MX2020007759A - Compuestos para el tratamiento de trastornos dependientes de cinasas. - Google Patents
Compuestos para el tratamiento de trastornos dependientes de cinasas.Info
- Publication number
- MX2020007759A MX2020007759A MX2020007759A MX2020007759A MX2020007759A MX 2020007759 A MX2020007759 A MX 2020007759A MX 2020007759 A MX2020007759 A MX 2020007759A MX 2020007759 A MX2020007759 A MX 2020007759A MX 2020007759 A MX2020007759 A MX 2020007759A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- kinase
- treatment
- formula
- dependent disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622629P | 2018-01-26 | 2018-01-26 | |
| US201862622626P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015289 WO2019148036A1 (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007759A true MX2020007759A (es) | 2020-09-24 |
Family
ID=65409542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007759A MX2020007759A (es) | 2018-01-26 | 2019-01-25 | Compuestos para el tratamiento de trastornos dependientes de cinasas. |
| MX2022014351A MX2022014351A (es) | 2018-01-26 | 2020-07-22 | Compuestos para el tratamiento de trastornos dependientes de cinasas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014351A MX2022014351A (es) | 2018-01-26 | 2020-07-22 | Compuestos para el tratamiento de trastornos dependientes de cinasas. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11708367B2 (enExample) |
| EP (2) | EP3743068B1 (enExample) |
| JP (2) | JP7307733B2 (enExample) |
| KR (1) | KR102759973B1 (enExample) |
| CN (1) | CN112312909B (enExample) |
| AU (1) | AU2019212719B2 (enExample) |
| CA (1) | CA3088127A1 (enExample) |
| CL (1) | CL2020001930A1 (enExample) |
| CO (1) | CO2020010467A2 (enExample) |
| CR (2) | CR20250117A (enExample) |
| IL (2) | IL302626B2 (enExample) |
| MA (1) | MA51672A (enExample) |
| MX (2) | MX2020007759A (enExample) |
| PE (1) | PE20210044A1 (enExample) |
| PH (1) | PH12020551059A1 (enExample) |
| SA (1) | SA520412488B1 (enExample) |
| SG (1) | SG11202006945PA (enExample) |
| UA (1) | UA128348C2 (enExample) |
| WO (1) | WO2019148036A1 (enExample) |
| ZA (1) | ZA202004065B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006945PA (en) * | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| CN115244041A (zh) * | 2020-03-10 | 2022-10-25 | 南京明德新药研发有限公司 | 乙烯基取代吡啶类化合物 |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| FI4143169T3 (fi) | 2020-04-30 | 2026-06-08 | Exelixis Inc | Kinaasi-inhibiittorin valmistusmenetelmät |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN117164527B (zh) * | 2022-05-25 | 2026-02-17 | 大连理工大学 | 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| WO2005009387A2 (en) | 2003-07-23 | 2005-02-03 | X-Ceptor Therapeutics Inc. | Azepine derivatives as pharmaceutical agents |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| AU2009303602B2 (en) | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| EP2213686A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| EP2214019A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| US20130017546A1 (en) | 2009-10-26 | 2013-01-17 | Externautics S.P.A. | Breast Tumor Markers and Methods of Use Thereof |
| WO2011051278A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Lung tumor markers and methods of use thereof |
| WO2011051276A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Colon and rectal tumor markers and methods of use thereof |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| EP2383578A1 (en) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Tumor marker and methods of use thereof |
| SG187064A1 (en) | 2010-07-14 | 2013-02-28 | Zhejiang Beta Pharma Inc | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| US10359428B2 (en) | 2013-06-14 | 2019-07-23 | Externautics S.P.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| JP6696908B2 (ja) | 2014-04-25 | 2020-05-20 | エグゼリクシス， インコーポレイテッド | 肺腺癌の治療方法 |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN110437145A (zh) | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| SG11202006945PA (en) * | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
-
2019
- 2019-01-25 SG SG11202006945PA patent/SG11202006945PA/en unknown
- 2019-01-25 UA UAA202005478A patent/UA128348C2/uk unknown
- 2019-01-25 PE PE2020001120A patent/PE20210044A1/es unknown
- 2019-01-25 WO PCT/US2019/015289 patent/WO2019148036A1/en not_active Ceased
- 2019-01-25 CR CR20250117A patent/CR20250117A/es unknown
- 2019-01-25 MX MX2020007759A patent/MX2020007759A/es unknown
- 2019-01-25 CN CN201980021547.0A patent/CN112312909B/zh active Active
- 2019-01-25 KR KR1020207024577A patent/KR102759973B1/ko active Active
- 2019-01-25 JP JP2020540750A patent/JP7307733B2/ja active Active
- 2019-01-25 US US16/964,228 patent/US11708367B2/en active Active
- 2019-01-25 IL IL302626A patent/IL302626B2/en unknown
- 2019-01-25 IL IL276028A patent/IL276028B2/en unknown
- 2019-01-25 CR CR20200355A patent/CR20200355A/es unknown
- 2019-01-25 EP EP19704968.7A patent/EP3743068B1/en active Active
- 2019-01-25 CA CA3088127A patent/CA3088127A1/en active Pending
- 2019-01-25 EP EP26173753.0A patent/EP4789723A2/en active Pending
- 2019-01-25 AU AU2019212719A patent/AU2019212719B2/en active Active
- 2019-01-25 MA MA051672A patent/MA51672A/fr unknown
-
2020
- 2020-07-03 ZA ZA2020/04065A patent/ZA202004065B/en unknown
- 2020-07-09 PH PH12020551059A patent/PH12020551059A1/en unknown
- 2020-07-22 MX MX2022014351A patent/MX2022014351A/es unknown
- 2020-07-23 CL CL2020001930A patent/CL2020001930A1/es unknown
- 2020-07-23 SA SA520412488A patent/SA520412488B1/ar unknown
- 2020-08-25 CO CONC2020/0010467A patent/CO2020010467A2/es unknown
-
2023
- 2023-03-22 JP JP2023045583A patent/JP7596427B2/ja active Active
- 2023-06-13 US US18/334,113 patent/US12195475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016051A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| CL2020001930A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| MX2020004534A (es) | Moduladores de la vía integrada del estrés. | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| CO2021006098A2 (es) | Moduladores de profármacos de la vía de estrés integrada | |
| MX2020004538A (es) | Moduladores de la vía de estrés integrada. | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| MX2020001103A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| CU20200046A7 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| MX2020004519A (es) | Moduladores de la vía de estrés integrada. | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| ECSP21080096A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| CA3139156A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| GEP20227437B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| ECSP067096A (es) | Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| EA202091790A1 (ru) | Соединения для лечения киназозависимых расстройств | |
| EA202091789A1 (ru) | Соединения для лечения киназозависимых расстройств | |
| EA202091110A1 (ru) | Модуляторы интегрированного стресса | |
| EA202091277A1 (ru) | Кристаллические формы n-(4-(4-(циклопропилметил)пиперазин-1-карбонил)фенил)хинолин-8-сульфонамида |